141 related articles for article (PubMed ID: 37075583)
1. Effect of hypoxia on HIF-1α and NOS3 expressions in CD34
Şoroğlu CV; Uslu-Bıçak İ; Toprak SF; Yavuz AS; Sözer S
Adv Med Sci; 2023 Sep; 68(2):169-175. PubMed ID: 37075583
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factors are increased in circulating granulocytes and CD34
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Nienhold R; Diklić M; Djikić D; Leković D; Bulat T; Marković D; Gotić M; Noguchi CT; Schechter AN; Skoda RC; Čokić VP
Mol Carcinog; 2017 Feb; 56(2):567-579. PubMed ID: 27341002
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J; Chatain N; Hubrich A; Maié T; Costa IG; Denecke B; Han L; Küstermann C; Sontag S; Seré K; Strathmann K; Zenke M; Schuppert A; Brümmendorf TH; Kranc KR; Koschmieder S; Gezer D
Leukemia; 2020 Apr; 34(4):1062-1074. PubMed ID: 31728053
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD133+/–CD34– Have Increased c-
Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
[TBL] [Abstract][Full Text] [Related]
5. [Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
Fu J; Xu Q; Zhao Y; Liu G; Cheng Z; Liang W; Xie X; Gu L
Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(46):3727-32. PubMed ID: 26850010
[TBL] [Abstract][Full Text] [Related]
6. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.
Rinaldi CR; Rinaldi P; Alagia A; Gemei M; Esposito N; Formiggini F; Martinelli V; Senyuk V; Nucifora G; Pane F
Blood; 2010 Dec; 116(26):6023-6. PubMed ID: 20861460
[TBL] [Abstract][Full Text] [Related]
7. VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms.
Subotički T; Mitrović Ajtić O; Živković E; Diklić M; Đikić D; Tošić M; Beleslin-Čokić B; Dragojević T; Gotić M; Santibanez JF; Čokić V
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206393
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
9. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
Chen YX; Li Y; Zhang LY; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
[TBL] [Abstract][Full Text] [Related]
10. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
Lin X; Rice KL; Buzzai M; Hexner E; Costa FF; Kilpivaara O; Mullally A; Soares MB; Ebert BL; Levine R; Licht JD
Leukemia; 2013 Feb; 27(2):344-52. PubMed ID: 22864358
[TBL] [Abstract][Full Text] [Related]
11. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
12. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
14. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
15. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
16. Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo.
Sozer S; Ishii T; Fiel MI; Wang J; Wang X; Zhang W; Godbold J; Xu M; Hoffman R
Blood Cells Mol Dis; 2009; 43(3):304-12. PubMed ID: 19762257
[TBL] [Abstract][Full Text] [Related]
17. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.
Fernandes de Oliveira Costa A; Olops Marani L; Mantello Bianco T; Queiroz Arantes A; Aparecida Lopes I; Antonio Pereira-Martins D; Carvalho Palma L; Santos Scheucher P; Lilian Dos Santos Schiavinato J; Sarri Binelli L; Araújo Silva C; Kobayashi SS; Agostinho Machado-Neto J; Magalhães Rego E; Samuel Welner R; Lobo de Figueiredo-Pontes L
Front Immunol; 2022; 13():768592. PubMed ID: 36211444
[TBL] [Abstract][Full Text] [Related]
18. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
19. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]